Protecting Health, Promoting Life

The Kenya BioVax Institute was established in 2021 to manufacture and commercialize human vaccines and other health products and technologies.

Here is our Overview
CEO BioVax PIc

KBI through its research and development (R&D), partnerships and collaborations would contribute to the eradication of communicable and non-communicable diseases through novel vaccines and other biotherapeutics. Local vaccine manufacturing would assure access of vaccines to all in the country’s universal health coverage (UHC) agenda

Dr. Michael Lusiola, Former MD/CEOKenya BioVax Institute, Nairobi.